☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Triple Class
Oncopeptides' Pepaxto (melphalan flufenamide) Receives the US FDA's Approval for Triple Class Refractory Multiple Myeloma
March 1, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.